- FactSet Research Systems Inc (NYSE:FDS) reported first-quarter FY23 sales growth of 18.9% year-on-year to $504.81 million, missing the consensus of $510.17 million.
- Organic Annual Subscription Value (ASV) plus professional services were $2 billion at November 30, 2022, compared with $1.7 billion at November 30, 2021.
- Adjusted EPS of $3.99 beat the consensus of $3.61.
- GAAP operating margin of 34.1% expanded 517 bps Y/Y. Adjusted operating margin expanded 471 bps to 38.3%.
- FactSet held $437.1 million in cash and equivalents as of November 30, 2022.
- Adjusted EBITDA increased 38.2% to $200.4 million.
- “While macro uncertainties persist, FactSet has historically grown through market cycles, and I’m confident in our business and pipeline heading into the second quarter,” CEO Phil Snow said.
- Outlook, reaffirmed: FactSet expects FY23 revenue of $2.100 billion – $2.115 billion, against the consensus of $2.1 billion.
- FactSet forecasts adjusted EPS guidance of $14.50 – $14.90 versus the consensus of $14.79.
- Price Action: FDS shares traded lower by 0.98% at $415.79 on the last check Tuesday.
Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO
Pharmaceutical executive Scott Plesha named CEOLead product ZELSUVMI expected to be commercially available in late 2024Ligand Pharmaceuticals (NASDAQ:LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a
